Activation of Yap1/Taz signaling in ischemic heart disease and dilated cardiomyopathy

Ning Hou, Ying Wen, Xun Yuan, Haodong Xu, Xuejun Wang, Faqian Li, Bo Ye

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Genetic manipulation of key components of the evolutionally conserved Hippo pathway has shown that the precise control of these signaling molecules is critical to cardiac development and response to stresses. However, how this pathway is involved in the progression of cardiac dysfunction in different heart diseases remains unclear. We investigated the expressional levels and subcellular localization of Yap1, Taz, and Tead1 and determined Hippo target gene expression in failing human hearts with ischemic heart disease (IHD) and idiopathic dilated cardiomyopathy (IDC) and mouse desmin-related cardiomyopathy (DES). Our results demonstrated that Yap1, Taz, and Tead1 were significantly increased in failing human and DES hearts compared with the non-failing controls (NFH) or wild type (WT) mouse hearts at both mRNA and protein levels. Interestingly, adult human and mouse hearts had more Taz than Yap1 by mRNA and protein expression and their increases in diseased hearts were proportional and did not change Yap1/Taz ratio. Yap1, Taz, and Tead1 were accumulated in the nuclear fraction and cardiomyocyte nuclei of diseased hearts. The ratio of Yap1 phosphorylated at serine 127 (human) or serine 112 (mouse) to the total Yap1 (pYap1/Yap1) was significantly lower in the nuclear fraction of diseased hearts than that in normal controls. More importantly, Hippo downstream targets Ankrd1, Ctgf, and Cyr61 were transcriptionally elevated in the diseased hearts. These results suggest that Yap1/Taz signaling is activated in human and mouse dysfunctional hearts. Further investigation with relevant animal models will determine whether this pathway is a potential target for preventing and reversing abnormal remodeling during the progression of different cardiac disorders.

Original languageEnglish (US)
Pages (from-to)267-275
Number of pages9
JournalExperimental and Molecular Pathology
Volume103
Issue number3
DOIs
StatePublished - Dec 2017

Fingerprint

Dilated Cardiomyopathy
Myocardial Ischemia
Heart Diseases
Chemical activation
Desmin
Cardiomyopathies
Serine
Messenger RNA
Cardiac Myocytes
Proteins
Animal Models
Gene Expression
Gene expression
Animals
Molecules

Keywords

  • Heart failure
  • Hippo
  • Taz
  • Yap1

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Clinical Biochemistry

Cite this

Activation of Yap1/Taz signaling in ischemic heart disease and dilated cardiomyopathy. / Hou, Ning; Wen, Ying; Yuan, Xun; Xu, Haodong; Wang, Xuejun; Li, Faqian; Ye, Bo.

In: Experimental and Molecular Pathology, Vol. 103, No. 3, 12.2017, p. 267-275.

Research output: Contribution to journalArticle

Hou, Ning ; Wen, Ying ; Yuan, Xun ; Xu, Haodong ; Wang, Xuejun ; Li, Faqian ; Ye, Bo. / Activation of Yap1/Taz signaling in ischemic heart disease and dilated cardiomyopathy. In: Experimental and Molecular Pathology. 2017 ; Vol. 103, No. 3. pp. 267-275.
@article{85d3eefa094d4512afbd1324dd5f7acf,
title = "Activation of Yap1/Taz signaling in ischemic heart disease and dilated cardiomyopathy",
abstract = "Genetic manipulation of key components of the evolutionally conserved Hippo pathway has shown that the precise control of these signaling molecules is critical to cardiac development and response to stresses. However, how this pathway is involved in the progression of cardiac dysfunction in different heart diseases remains unclear. We investigated the expressional levels and subcellular localization of Yap1, Taz, and Tead1 and determined Hippo target gene expression in failing human hearts with ischemic heart disease (IHD) and idiopathic dilated cardiomyopathy (IDC) and mouse desmin-related cardiomyopathy (DES). Our results demonstrated that Yap1, Taz, and Tead1 were significantly increased in failing human and DES hearts compared with the non-failing controls (NFH) or wild type (WT) mouse hearts at both mRNA and protein levels. Interestingly, adult human and mouse hearts had more Taz than Yap1 by mRNA and protein expression and their increases in diseased hearts were proportional and did not change Yap1/Taz ratio. Yap1, Taz, and Tead1 were accumulated in the nuclear fraction and cardiomyocyte nuclei of diseased hearts. The ratio of Yap1 phosphorylated at serine 127 (human) or serine 112 (mouse) to the total Yap1 (pYap1/Yap1) was significantly lower in the nuclear fraction of diseased hearts than that in normal controls. More importantly, Hippo downstream targets Ankrd1, Ctgf, and Cyr61 were transcriptionally elevated in the diseased hearts. These results suggest that Yap1/Taz signaling is activated in human and mouse dysfunctional hearts. Further investigation with relevant animal models will determine whether this pathway is a potential target for preventing and reversing abnormal remodeling during the progression of different cardiac disorders.",
keywords = "Heart failure, Hippo, Taz, Yap1",
author = "Ning Hou and Ying Wen and Xun Yuan and Haodong Xu and Xuejun Wang and Faqian Li and Bo Ye",
year = "2017",
month = "12",
doi = "10.1016/j.yexmp.2017.11.006",
language = "English (US)",
volume = "103",
pages = "267--275",
journal = "Experimental and Molecular Pathology",
issn = "0014-4800",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Activation of Yap1/Taz signaling in ischemic heart disease and dilated cardiomyopathy

AU - Hou, Ning

AU - Wen, Ying

AU - Yuan, Xun

AU - Xu, Haodong

AU - Wang, Xuejun

AU - Li, Faqian

AU - Ye, Bo

PY - 2017/12

Y1 - 2017/12

N2 - Genetic manipulation of key components of the evolutionally conserved Hippo pathway has shown that the precise control of these signaling molecules is critical to cardiac development and response to stresses. However, how this pathway is involved in the progression of cardiac dysfunction in different heart diseases remains unclear. We investigated the expressional levels and subcellular localization of Yap1, Taz, and Tead1 and determined Hippo target gene expression in failing human hearts with ischemic heart disease (IHD) and idiopathic dilated cardiomyopathy (IDC) and mouse desmin-related cardiomyopathy (DES). Our results demonstrated that Yap1, Taz, and Tead1 were significantly increased in failing human and DES hearts compared with the non-failing controls (NFH) or wild type (WT) mouse hearts at both mRNA and protein levels. Interestingly, adult human and mouse hearts had more Taz than Yap1 by mRNA and protein expression and their increases in diseased hearts were proportional and did not change Yap1/Taz ratio. Yap1, Taz, and Tead1 were accumulated in the nuclear fraction and cardiomyocyte nuclei of diseased hearts. The ratio of Yap1 phosphorylated at serine 127 (human) or serine 112 (mouse) to the total Yap1 (pYap1/Yap1) was significantly lower in the nuclear fraction of diseased hearts than that in normal controls. More importantly, Hippo downstream targets Ankrd1, Ctgf, and Cyr61 were transcriptionally elevated in the diseased hearts. These results suggest that Yap1/Taz signaling is activated in human and mouse dysfunctional hearts. Further investigation with relevant animal models will determine whether this pathway is a potential target for preventing and reversing abnormal remodeling during the progression of different cardiac disorders.

AB - Genetic manipulation of key components of the evolutionally conserved Hippo pathway has shown that the precise control of these signaling molecules is critical to cardiac development and response to stresses. However, how this pathway is involved in the progression of cardiac dysfunction in different heart diseases remains unclear. We investigated the expressional levels and subcellular localization of Yap1, Taz, and Tead1 and determined Hippo target gene expression in failing human hearts with ischemic heart disease (IHD) and idiopathic dilated cardiomyopathy (IDC) and mouse desmin-related cardiomyopathy (DES). Our results demonstrated that Yap1, Taz, and Tead1 were significantly increased in failing human and DES hearts compared with the non-failing controls (NFH) or wild type (WT) mouse hearts at both mRNA and protein levels. Interestingly, adult human and mouse hearts had more Taz than Yap1 by mRNA and protein expression and their increases in diseased hearts were proportional and did not change Yap1/Taz ratio. Yap1, Taz, and Tead1 were accumulated in the nuclear fraction and cardiomyocyte nuclei of diseased hearts. The ratio of Yap1 phosphorylated at serine 127 (human) or serine 112 (mouse) to the total Yap1 (pYap1/Yap1) was significantly lower in the nuclear fraction of diseased hearts than that in normal controls. More importantly, Hippo downstream targets Ankrd1, Ctgf, and Cyr61 were transcriptionally elevated in the diseased hearts. These results suggest that Yap1/Taz signaling is activated in human and mouse dysfunctional hearts. Further investigation with relevant animal models will determine whether this pathway is a potential target for preventing and reversing abnormal remodeling during the progression of different cardiac disorders.

KW - Heart failure

KW - Hippo

KW - Taz

KW - Yap1

UR - http://www.scopus.com/inward/record.url?scp=85034452593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034452593&partnerID=8YFLogxK

U2 - 10.1016/j.yexmp.2017.11.006

DO - 10.1016/j.yexmp.2017.11.006

M3 - Article

C2 - 29154888

AN - SCOPUS:85034452593

VL - 103

SP - 267

EP - 275

JO - Experimental and Molecular Pathology

JF - Experimental and Molecular Pathology

SN - 0014-4800

IS - 3

ER -